Selective serotonin reuptake inhibitors (SSRIs) are a class of antidepressant medications that increase synaptic serotonin concentrations by inhibiting the serotonin transporter (SERT). This mechanism enhances serotonergic neurotransmission and alleviates symptoms of depression and anxiety. In neurodegenerative diseases, SSRIs are frequently prescribed to manage neuropsychiatric symptoms, though their use requires careful consideration of potential benefits and risks[1].
SSRIs work by blocking the serotonin transporter (SERT), which is responsible for reuptaking serotonin from the synaptic cleft back into the presynaptic neuron. By inhibiting SERT, SSRIs increase the availability of serotonin in the synaptic space, enhancing postsynaptic receptor activation. The primary SSRIs include:
Beyond increasing synaptic serotonin, SSRIs produce downstream effects including:
Depression affects 30-50% of Alzheimer's disease patients throughout the disease course. SSRIs are commonly used as first-line treatment for depressive symptoms in AD, though several considerations apply[2]:
Depression occurs in approximately 40-50% of Parkinson's disease patients and significantly impacts quality of life. SSRIs are frequently used, but important interactions exist[3]:
SSRIs are commonly prescribed for post-stroke depression and vascular depression, which frequently co-occurs with vascular dementia. The vascular depression hypothesis suggests that cerebrovascular disease predisposes to late-life depression, creating a bidirectional relationship with cognitive decline[4].
Depression affects up to 44% of ALS patients. SSRIs provide benefit for depressive symptoms and may have modest effects on survival. Additionally, SSRIs with anxiolytic properties help manage anxiety associated with the progressive nature of the disease.
Serotonin syndrome is a potentially life-threatening condition caused by excessive serotonergic activity. In neurodegenerative disease patients, risk factors include[5]:
Symptoms include altered mental status, autonomic instability, and neuromuscular excitability. Prevention involves avoiding contraindicated combinations and starting with low doses.
SSRIs inhibit platelet serotonin uptake, impairing platelet aggregation and increasing bleeding risk. This is particularly relevant for patients:
Elderly patients are at risk for SSRIs-induced hyponatremia (SIADH), particularly in the first weeks of treatment. Monitoring of sodium levels is recommended, especially in patients with existing electrolyte abnormalities.
Certain SSRIs (citalopram, escitalopram) dose-dependently prolong the QT interval. Electrocardiographic monitoring is recommended in patients with pre-existing cardiac conditions or those on other QT-prolonging medications.
| SSRI | MAO-BI | Anticholinergic | Anticoagulants | QT Risk |
|---|---|---|---|---|
| Fluoxetine | Caution | Low | Increased | Low |
| Sertraline | Caution | None | Increased | Low |
| Paroxetine | Caution | High | Increased | Low |
| Citalopram | Caution | Low | Increased | High |
| Escitalopram | Caution | Low | Increased | Moderate |
Research areas for SSRIs in neurodegenerative diseases include:
SSRIs remain valuable tools for managing depression and anxiety in neurodegenerative diseases. Careful patient selection, appropriate monitoring, and awareness of drug interactions optimize their safety and efficacy. While not disease-modifying, SSRIs significantly improve quality of life for patients struggling with neuropsychiatric symptoms.
Riedel WJ, et al. SSRIs in neuroprotection. Eur Neuropsychopharmacol. 2022;55:34-48. 2022. ↩︎
Lyketos CG, et al. Depression in Alzheimer's disease: Overview and treatment. J Alzheimers Dis. 2021;79(3):1045-1062. 2021. ↩︎
Schapira AHV, et al. Non-motor symptoms in Parkinson's disease. Mov Disord. 2021;36(7):1583-1595. 2021. ↩︎
Taylor WD, et al. Vascular depression and cerebrovascular disease. Biol Psychiatry. 2023;93(1):38-47. 2023. ↩︎
Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2021;385(16):1524-1535. 2021. ↩︎